FDA Approves Atezolizumab for Lung Cancer

Article link

The FDA has approved atezolizumab (Tecentriq) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) who have progressed after a platinum-containing regimen and an FDA-approved targeted therapy for those patients harboring EGFR or ALK abnormalities. - See more at: http://www.onclive.com/web-exclusives/fda-approves-atezolizumab-for-lung-cancer#sthash.RnEGv2da.dpuf